The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Ziftomenib in relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML): Phase 1b/2 clinical activity and safety results from the pivotal KOMET-001 study.
 
Eunice Wang
Consulting or Advisory Role - Abbvie; Blueprint Medicines; Celgene/Bristol-Myers Squibb; CTI BioPharma Corp; Daiichi Sankyo/UCB Japan; GlaxoSmithKline; Immunogen; Johnson & Johnson/Janssen; Kite/Gilead; Kura Oncology; Novartis; Qiagen; Rigel; Ryvu Therapeutics; Schrodinger; SERVIER; Stemline Therapeutics; Sumitomo Pharma Oncology; Syndax; Takeda
Speakers' Bureau - Astellas Pharma; Daiichi Sankyo/UCB Japan; DAVA Pharmaceuticals; Pfizer
Other Relationship - Abbvie/Genentech; Gilead Sciences; Gilead Sciences; UpToDate
 
Pau Montesinos
Consulting or Advisory Role - Abbvie; Daiichi Sankyo; Jazz Pharmaceuticals; Otsuka; Pfizer; SERVIER
Speakers' Bureau - Celgene; Daiichi Sankyo; Otsuka
Research Funding - Abbvie (Inst); Celgene (Inst); Daiichi Sankyo Europe GmbH (Inst); Janssen-Cilag (Inst); Pfizer (Inst); Servier (Inst)
Travel, Accommodations, Expenses - Amgen
 
Ghayas Issa
Consulting or Advisory Role - Abbvie; Kura Oncology; Novartis; NuProbe; Sanofi; Syndax
Research Funding - Astex Pharmaceuticals (Inst); Cullinan Oncology; Kura Oncology (Inst); Merck; Novartis (Inst); NuProbe (Inst); Syndax (Inst)
 
James Foran
Stock and Other Ownership Interests - Aurinia Pharmaceuticals
Consulting or Advisory Role - Autolus Therapeutics; Cardinal Health; CTI BioPharma Corp; Medscape; Peerview; Remix Therapeutics; Syndax
Research Funding - Abbvie (Inst); Actinium Pharmaceuticals (Inst); Astellas Pharma (Inst); Celgene/Bristol-Myers Squibb (Inst); Chordia Therapeutics; Kura Oncology (Inst); Novartis (Inst); Roivant (Inst); Sellas Life Sciences (Inst); SERVIER (Inst)
Travel, Accommodations, Expenses - Peerview
 
Harry Erba
Consulting or Advisory Role - Abbvie/Genentech; Agios; Amgen; Astellas Pharma; Bristol-Myers Squibb/Celgene; Celgene; Daiichi Sankyo; Glycomimetics; Immunogen; Incyte; Janssen Oncology; Jazz Pharmaceuticals; Kura Oncology; Macrogenics; Novartis; Pfizer; Schrodinger; SERVIER; Stemline Therapeutics; Sumitomo Dainippon Pharma Oncology; Takeda; Trillium Therapeutics
Speakers' Bureau - Abbvie; Agios; Bristol Myers Squibb Foundation; Incyte; Jazz Pharmaceuticals; Novartis; SERVIER; Syndax
Research Funding - Abbvie (Inst); Abbvie (Inst); Agios (Inst); ALX Oncology (Inst); Amgen (Inst); Aptose Biosciences (Inst); Ascentage Pharma (Inst); Daiichi Sankyo (Inst); FORMA Therapeutics (Inst); Gilead/Forty Seven (Inst); Glycomimetics (Inst); Immunogen (Inst); Jazz Pharmaceuticals (Inst); Kura Oncology (Inst); Macrogenics (Inst); Novartis (Inst); Oryzon Genomics (Inst); PTC Therapeutics (Inst); SERVIER (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Taiho Oncology (Inst)
Other Relationship - Bristol-Myers Squibb/Celgene; Celgene; Glycomimetics
(OPTIONAL) Uncompensated Relationships - Daiichi Sankyo
 
Eduardo Rodríguez-Arbolí
Consulting or Advisory Role - Astellas Pharma; Kura Oncology; Laboratoires Delbert; SERVIER
Speakers' Bureau - AbbVie; Jazz Pharmaceuticals
Travel, Accommodations, Expenses - AbbVie; Jazz Pharmaceuticals
 
Kateryna Fedorov
No Relationships to Disclose
 
Mael Heiblig
No Relationships to Disclose
 
Florian Heidel
Consulting or Advisory Role - Abbvie; AOP Health; Celgene; CTI; GlaxoSmithKline; Janssen; Merck; Novartis
Research Funding - Celgene; CTI; Novartis
 
Jessica Altman
Consulting or Advisory Role - Abbvie; Aptitude Health; Astellas Pharma; BioSight; Bluebird Bio; Curio Science; Curio Science; Daiichi Sankyo/Lilly; Dark Blue Therapeutics; Gilead Sciences; GlycoMimetics; HMP Education; Kura Oncology; MD Education; Rigel; Stemline Therapeutics; Treadwell Therapeutics; VJ HemOnc
Research Funding - Abbvie (Inst); Agios (Inst); ALX Oncology (Inst); Amgen (Inst); Aptose Biosciences (Inst); Astellas Pharma (Inst); Biosight (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Immunogen (Inst); Kartos Therapeutics (Inst); Kura Oncology (Inst); Kura Oncology (Inst); Loxo (Inst); Pfizer (Inst); Takeda (Inst); Telios (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Biosight; Daiichi Sankyo
Other Relationship - Imedex/HMP; NCCN; NCI; Peerview
 
Maria Baer
Research Funding - Abbvie (Inst); Ascentage Pharma (Inst); Astellas Pharma (Inst); Curadev (Inst); Kura Oncology (Inst); Takeda (Inst)
 
Lionel Adès
Honoraria - Abbvie; Celgene; Jazz Pharmaceuticals; Novartis
Research Funding - Celgene (Inst)
 
Kristen Pettit
Consulting or Advisory Role - AbbVie; Merck
Travel, Accommodations, Expenses - Merck
 
Pierre Peterlin
Honoraria - Bristol-Myers Squibb; Jazz Pharmaceuticals; SERVIER
Consulting or Advisory Role - Bristol-Myers Squibb; SERVIER
Research Funding - Abbvie (Inst); Jazz Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo; Jazz Pharmaceuticals
 
Cristina Papayannidis
Honoraria - Abbvie; Amgen; Astellas Pharma; Bristol-Myers Squibb; Incyte; Istituto Gentili; Janssen; Menarini Group; Novartis; Pfizer; SERVIER
Consulting or Advisory Role - Abbvie; Astellas Pharma; Blueprint Pharmaceutic; Delbert Laboratoires; GlaxoSmithKline; Istituto Gentili; Janssen; Jazz Pharmaceuticals; Novartis; Pfizer; Syndax
 
Zijing Zhang
Employment - Kura Oncology
Stock and Other Ownership Interests - Kura Oncology
 
Marcie Riches
Employment - Kura Oncology
Stock and Other Ownership Interests - Kura Oncology
Travel, Accommodations, Expenses - Kura Oncology
 
Daniel Corum
Employment - Kura Oncology
Stock and Other Ownership Interests - Kura Oncology
Patents, Royalties, Other Intellectual Property - Kura Oncology
 
Mollie Leoni
Employment - Kura Oncology
Stock and Other Ownership Interests - Kura Oncology
Patents, Royalties, Other Intellectual Property - Kura Oncology
 
Amir Fathi
Consulting or Advisory Role - Abbvie; Astellas Pharma; AstraZeneca/UK; Bristol-Myers Squibb; Daiichi Sankyo; Genentech; Gilead Sciences; Immunocore; Ipsen; Kura Oncology; Menarini; Orum Therapeutics; Pfizer; Prelude Corporation; Remix Therapeutics; Rigel; Schrodinger; SERVIER; Syndax; Takeda
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Kura Oncology (Inst); SERVIER (Inst)